1[1]Lazarou J,Pomeranz BH,Corey PN.Incidence of adverse drug reactions in hospitalized patients:a meta-analysis of prospective studies[J].JAMA.1998,279(15):1200-1205.
8[9]Fattinger K,Roos M,Vergeres P,Holenstein C,Kind B,Masche U,Stocker DN,Braunschweig S,Kullak-Ublick GA,Galeazzi RL,Follath F,Gasser T,Meier PJ.Epidemiology of drug exposure and adverse drug reactions in two swiss departments of internal medicine[J].Br J Clin Pharmacol.2000,49(2):158-167.
9[10]Amery WK.Post-marketing drug safety management:a pharmaceutical industry perspective.Int J of risk & safety in medicine[J].Special issue.1994,5(2/3):243-250.
10[11]Psaty BM,Koepsell TD,LoGerfo JP,et al.β-blockers and primary prevention of coronary heart disease in patients with high blood pressure[J].JAMA 1989,261:2087-2094.
